Dr. Pomper focuses his research on molecular imaging and therapy for cancer and central nervous system disorders. His work has resulted in nearly 500 peer-reviewed publications in scientific journals, and a number of patents and presentations at professional conferences throughout the world. 

While his work has involved molecular-genetic imaging, nanomedicine, and generation of new positron emission tomography (PET)-based agents for neuroinflammation, his greatest effort has been in the discovery and development of small molecules targeting the prostate-specific membrane antigen (PSMA). He created the first small molecules for imaging PSMA, and the first commercial PSMA-targeted PET agent (PYLARIFY®). His group also created the first PSMA-targeted imaging and therapeutic (theranostic) agents incorporating a radiometal. Compounds of the same chemical class have been approved by the FDA and are used worldwide to help manage patients with prostate cancer.